Total Equity
The latest quarterly total equity is $1.30B with a quarterly period change of (14.03%). Total equity, also called shareholders' equity or book value, is assets minus liabilities.
PODD Total Equity
Reported quarterly total equity; no daily interpolation.
Quarterly Total Equity History
| Period | Total Equity | % Change |
|---|---|---|
| Q1 2026 | $1.30B | (14.03%) |
| Q4 2025 | $1.52B | +9.47% |
| Q3 2025 | $1.38B | (5.39%) |
| Q2 2025 | $1.46B | +9.93% |
| Q1 2025 | $1.33B | +9.83% |
| Q4 2024 | $1.21B | +8.37% |
| Q3 2024 | $1.12B | +11.98% |
| Q2 2024 | $998.40M | +26.27% |
| Q1 2024 | $790.70M | +7.92% |
| Q4 2023 | $732.70M | +20.61% |
| Q3 2023 | $607.50M | +9.68% |
| Q2 2023 | $553.90M | +10.16% |
| Q1 2023 | $502.80M | +5.54% |
| Q4 2022 | $476.40M | +11.31% |
| Q3 2022 | $428.00M | +1.33% |
| Q2 2022 | $422.40M | (5.44%) |
| Q1 2022 | $446.70M | (19.70%) |
| Q4 2021 | $556.30M | +11.73% |
| Q3 2021 | $497.90M | +8.45% |
| Q2 2021 | $459.10M | (21.56%) |
| Q1 2021 | $585.30M | (3.03%) |
| Q4 2020 | $603.60M | +1.45% |
| Q3 2020 | $595.00M | +5.63% |
| Q2 2020 | $563.30M | +854.75% |
| Q1 2020 | $59.00M | (22.27%) |
| Q4 2019 | $75.90M | (49.59%) |
| Q3 2019 | $150.57M | (39.72%) |
| Q2 2019 | $249.78M | +11.69% |
| Q1 2019 | $223.63M | +5.44% |
| Q4 2018 | $212.10M | +7.16% |
| Q3 2018 | $197.93M | +10.48% |
| Q2 2018 | $179.15M | +5.03% |
| Q1 2018 | $170.57M | +7.60% |
| Q4 2017 | $158.52M | +113.48% |
| Q3 2017 | $74.25M | +14.72% |
| Q2 2017 | $64.72M | +1.79% |
| Q1 2017 | $63.59M | +0.69% |
| Q4 2016 | $63.15M | (2.99%) |
| Q3 2016 | $65.09M | +137.19% |
| Q2 2016 | $27.44M | +3.97% |
| Q1 2016 | $26.40M | (22.48%) |
| Q4 2015 | $34.05M | (38.24%) |
| Q3 2015 | $55.13M | (21.52%) |
| Q2 2015 | $70.25M | (12.99%) |
| Q1 2015 | $80.74M | (3.68%) |
| Q4 2014 | $83.83M | +4.34% |
| Q3 2014 | $80.34M | +3.15% |
| Q2 2014 | $77.88M | (36.42%) |
| Q1 2014 | $122.49M | (1.69%) |
| Q4 2013 | $124.60M | +2.61% |
| Q3 2013 | $121.43M | (12.22%) |
| Q2 2013 | $138.34M | +6.78% |
| Q1 2013 | $129.55M | +193.25% |
| Q4 2012 | $44.18M | +12.94% |
| Q3 2012 | $39.11M | (18.09%) |
| Q2 2012 | $47.75M | (18.90%) |
| Q1 2012 | $58.88M | (17.53%) |
| Q4 2011 | $71.40M | (14.43%) |
| Q3 2011 | $83.44M | (11.33%) |
| Q2 2011 | $94.10M | +57.41% |
| Q1 2011 | $59.78M | (9.74%) |
| Q4 2010 | $66.23M | +97.67% |
| Q3 2010 | $33.51M | (23.82%) |
| Q2 2010 | $43.98M | +7.47% |
| Q1 2010 | $40.92M | (22.58%) |
| Q4 2009 | $52.86M | +17344.55% |
| Q3 2009 | $303,000 | +108.73% |
| Q2 2009 | ($3.47M) | (122.46%) |
| Q1 2009 | $15.46M | +261.65% |
| Q4 2008 | $4.27M | (86.50%) |
| Q3 2008 | $31.65M | (38.30%) |
| Q2 2008 | $51.29M | (30.35%) |
| Q1 2008 | $73.64M | (20.20%) |
| Q4 2007 | $92.28M | (4.18%) |
| Q3 2007 | $96.30M | (12.07%) |
| Q2 2007 | $109.52M | +196.86% |
| Q1 2007 | ($113.08M) | (11.11%) |
| Q4 2006 | ($101.77M) | (11.93%) |
| Q3 2006 | ($90.92M) | (37.56%) |
| Q4 2005 | ($66.09M) | - |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy